{
    "organizations": [],
    "uuid": "1cf10542cfc23282343f0bf122fc9db0a166475d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-avid-bioservices-selected-by-acume/brief-avid-bioservices-selected-by-acumen-pharmaceuticals-to-lead-process-development-and-clinical-manufacture-of-novel-alzheimers-disease-candidate-idUSFWN1QJ0TU",
    "ord_in_thread": 0,
    "title": "Avid Bioservices Selected By Acumen Pharmaceuticals To Lead Process Development And Clinical Manufacture Of Novel Alzheimer's Disease Candidate",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1 (Reuters) - Avid Bioservices Inc:\n* AVID BIOSERVICES SELECTED BY ACUMEN PHARMACEUTICALS TO LEAD PROCESS DEVELOPMENT AND CLINICAL MANUFACTURE OF NOVEL ALZHEIMERâ€™S DISEASE CANDIDATE\n* AVID BIOSERVICES - ACUMEN PHARMA SELECTED CO TO PROVIDE PROCESS DEVELOPMENT, CLINICAL MANUFACTURING SERVICES IN SUPPORT OF ACU193 Source text for Eikon:\n ",
    "published": "2018-03-01T21:08:00.000+02:00",
    "crawled": "2018-03-02T19:41:48.027+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "avid",
        "bioservices",
        "inc",
        "avid",
        "bioservices",
        "selected",
        "acumen",
        "pharmaceutical",
        "lead",
        "process",
        "development",
        "clinical",
        "manufacture",
        "novel",
        "alzheimer",
        "disease",
        "candidate",
        "avid",
        "bioservices",
        "acumen",
        "pharma",
        "selected",
        "co",
        "provide",
        "process",
        "development",
        "clinical",
        "manufacturing",
        "service",
        "support",
        "acu193",
        "source",
        "text",
        "eikon"
    ]
}